Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 11,439,100 | 11,302,800 | 8,768,000 | 9,353,402 | 9,498,600 |
| Cost of Goods | 2,170,800 | 2,170,200 | 1,673,500 | 1,788,000 | 1,860,100 |
| Gross Profit | 9,268,300 | 9,132,600 | 7,094,500 | 7,565,400 | 7,638,500 |
| Operating Expenses | 4,916,300 | 4,983,000 | 4,586,000 | 8,152,701 | 4,213,100 |
| Operating Income | 4,352,799 | 4,149,800 | 2,509,000 | -587,299 | 3,425,500 |
| Other Income | -2,764,399 | -632,600 | 27,100 | 3,096,099 | -2,998,300 |
| Pre-tax Income | 1,588,400 | 3,517,200 | 2,536,100 | 2,508,800 | 427,200 |
| Income Tax | 618,100 | 550,200 | 293,200 | 319,100 | 484,600 |
| Net Income Continuous | 970,300 | 2,967,000 | 2,242,900 | 2,189,700 | -57,400 |
| Net Income | $970,300 | $2,967,000 | $2,242,900 | $2,189,700 | $-57,400 |
| EPS Basic Total Ops | 1.08 | 3.29 | 2.49 | 2.43 | -0.06 |
| EPS Basic Continuous Ops | 1.08 | 3.29 | 2.49 | 2.43 | -0.06 |
| EPS Diluted Total Ops | 1.07 | 3.28 | 2.48 | 2.42 | -0.06 |
| EPS Diluted Continuous Ops | 1.07 | 3.28 | 2.48 | 2.42 | -0.06 |
| EPS Diluted Before Non-Recurring Items | 1.18 | 3.92 | 2.58 | 2.49 | 0.10 |
| EBITDA(a) | $4,819,600 | $4,564,200 | $2,909,600 | $-199,599 | $3,836,500 |